Theravance Biopharma
TBPH
113 hedge funds and large institutions have $568M invested in Theravance Biopharma in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 35 increasing their positions, 45 reducing their positions, and 15 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
1.37% more ownership
Funds ownership: 83.03% → 84.39% (+1.4%)
4% more call options, than puts
Call options by funds: $1.28M | Put options by funds: $1.24M
5% less capital invested
Capital invested by funds: $600M → $568M (-$32.8M)
7% less funds holding
Funds holding: 121 → 113 (-8)
22% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 45
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$26.1M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$8.45M |
| 3 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$7.6M |
| 4 |
NM
Newtyn Management
New York
|
+$6.11M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$17.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.07M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.71M |
| 4 |
Goldman Sachs
New York
|
-$3.62M |
| 5 |
Morgan Stanley
New York
|
-$2.55M |
TBPH Hedge Fund Activity: Q2 2022 in Review
113 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2022, worth a combined $568M — down 5.5% from $600M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TBPH and 9 opened new positions — a net loss of 6 holders — while 45 trimmed existing stakes and 35 added.
The largest buyer was Park West Asset Management, adding an estimated $26.1M. The largest seller was OrbiMed, cutting an estimated $17.4M.
- 113 institutional investors held Theravance Biopharma (TBPH) as of Q2 2022, down from 121 in Q1 2022.
- Funds reported $568M of Theravance Biopharma stock for Q2 2022, down 5.5% quarter-over-quarter.
- 9 funds opened new Theravance Biopharma positions in Q2 2022 and 15 closed out, a net change of -6 holders.
- The largest Theravance Biopharma buyer in Q2 2022 was Park West Asset Management, an estimated $26.1M added.
- The largest Theravance Biopharma seller in Q2 2022 was OrbiMed, an estimated $17.4M sold.
Based on aggregated 13F filings for Q2 2022.